MX2019000539A - Anticuerpos anti-il-22r. - Google Patents
Anticuerpos anti-il-22r.Info
- Publication number
- MX2019000539A MX2019000539A MX2019000539A MX2019000539A MX2019000539A MX 2019000539 A MX2019000539 A MX 2019000539A MX 2019000539 A MX2019000539 A MX 2019000539A MX 2019000539 A MX2019000539 A MX 2019000539A MX 2019000539 A MX2019000539 A MX 2019000539A
- Authority
- MX
- Mexico
- Prior art keywords
- antibodies
- antigen
- relates
- binding fragments
- cytokine
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/515—Complete light chain, i.e. VL + CL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Dermatology (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1612337.4A GB201612337D0 (en) | 2016-07-15 | 2016-07-15 | Ant-il-22r antibodies |
| PCT/EP2017/067923 WO2018011420A1 (en) | 2016-07-15 | 2017-07-14 | Anti-il-22r antibodies |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2019000539A true MX2019000539A (es) | 2019-10-04 |
Family
ID=56890507
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2019000539A MX2019000539A (es) | 2016-07-15 | 2017-07-14 | Anticuerpos anti-il-22r. |
Country Status (27)
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201612337D0 (en) | 2016-07-15 | 2016-08-31 | Argen-X N V | Ant-il-22r antibodies |
| MX2020013243A (es) * | 2018-06-05 | 2021-05-12 | Bioatla Inc | Anticuerpos anti-il-22, fragmentos de anticuerpo, sus inmunoconjugados y usos de los mismos. |
| CN110302363B (zh) * | 2019-07-04 | 2020-10-09 | 北京大学第三医院（北京大学第三临床医学院） | Il-22作为制备治疗pcos药物的应用及药物制剂 |
| TW202200623A (zh) * | 2020-05-29 | 2022-01-01 | 日商第一三共股份有限公司 | 對炎症性腸病之治療用抗體 |
| CN119836287A (zh) | 2022-06-03 | 2025-04-15 | 里奥制药有限公司 | Il-22r抗体的液体制剂 |
| WO2024184333A1 (en) | 2023-03-08 | 2024-09-12 | Leo Pharma A/S | Il-22r antibody for use in treating atopic dermatitis |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5892019A (en) | 1987-07-15 | 1999-04-06 | The United States Of America, As Represented By The Department Of Health And Human Services | Production of a single-gene-encoded immunoglobulin |
| EA009124B1 (ru) * | 2003-03-24 | 2007-10-26 | Займоджинетикс, Инк. | Антитела против il-20 и связывающие партнеры, а также способы их применения при воспалении |
| DK1812476T3 (da) * | 2004-10-22 | 2010-10-25 | Zymogenetics Inc | Anti-IL-22RA-antistoffer og bindingspartnere samt fremgangsmåder til anvendelse ved inflammation |
| WO2007126439A2 (en) * | 2005-12-02 | 2007-11-08 | Genentech, Inc. | Compositions and methods for the treatment of diseases and disorders associated with cytokine signaling involving antibodies that bind to il-22 and il-22r |
| GB2461546B (en) | 2008-07-02 | 2010-07-07 | Argen X Bv | Antigen binding polypeptides |
| WO2011061119A1 (en) * | 2009-11-19 | 2011-05-26 | Merck Serono S.A. | Humanized antibodies against human il-22ra |
| GB2476681B (en) | 2010-01-04 | 2012-04-04 | Argen X Bv | Humanized camelid VH, VK and VL immunoglobulin domains |
| GB2504139B (en) * | 2012-07-20 | 2014-12-31 | Argen X Bv | Antibodies to highly conserved targets produced by the immunisation of Camelidae species |
| EP2791169B1 (en) * | 2011-12-16 | 2017-07-19 | Synthon Biopharmaceuticals B.V. | Compounds and methods for treating inflammatory diseases |
| WO2014033252A1 (en) | 2012-08-31 | 2014-03-06 | arGEN-X BV | Method for producing antibody molecules having inter-species, intra-target cross-reactivity |
| US10093737B2 (en) * | 2013-03-01 | 2018-10-09 | Albert Einstein College Of Medicine, Inc. | HHLA2 as a novel inhibitor of human immune system and uses thereof |
| CN105601739B (zh) * | 2016-02-22 | 2019-01-18 | 王晨辉 | 一种人源化抗白介素22基因工程抗体及其应用 |
| GB201612337D0 (en) | 2016-07-15 | 2016-08-31 | Argen-X N V | Ant-il-22r antibodies |
-
2016
- 2016-07-15 GB GBGB1612337.4A patent/GB201612337D0/en not_active Ceased
-
2017
- 2017-07-14 MX MX2019000539A patent/MX2019000539A/es unknown
- 2017-07-14 SG SG11201900128XA patent/SG11201900128XA/en unknown
- 2017-07-14 HU HUE17746011A patent/HUE057615T2/hu unknown
- 2017-07-14 WO PCT/EP2017/067923 patent/WO2018011420A1/en not_active Ceased
- 2017-07-14 AU AU2017296094A patent/AU2017296094B2/en active Active
- 2017-07-14 EP EP17746011.0A patent/EP3484921B1/en active Active
- 2017-07-14 RU RU2019103991A patent/RU2758721C2/ru active
- 2017-07-14 MY MYPI2018002752A patent/MY197821A/en unknown
- 2017-07-14 KR KR1020197001500A patent/KR102571012B1/ko active Active
- 2017-07-14 CN CN201780053328.1A patent/CN109641966B/zh active Active
- 2017-07-14 LT LTEPPCT/EP2017/067923T patent/LT3484921T/lt unknown
- 2017-07-14 EP EP21208038.6A patent/EP4023674A3/en not_active Withdrawn
- 2017-07-14 CA CA3024370A patent/CA3024370A1/en active Pending
- 2017-07-14 UA UAA201901458A patent/UA125585C2/uk unknown
- 2017-07-14 PT PT177460110T patent/PT3484921T/pt unknown
- 2017-07-14 PL PL17746011T patent/PL3484921T3/pl unknown
- 2017-07-14 SI SI201731037T patent/SI3484921T1/sl unknown
- 2017-07-14 KR KR1020237028376A patent/KR20230128137A/ko not_active Ceased
- 2017-07-14 JP JP2019501641A patent/JP7163275B2/ja active Active
- 2017-07-14 HR HRP20220197TT patent/HRP20220197T1/hr unknown
- 2017-07-14 DK DK17746011.0T patent/DK3484921T3/da active
- 2017-07-14 RS RS20220105A patent/RS62884B1/sr unknown
- 2017-07-14 IL IL264262A patent/IL264262B2/en unknown
- 2017-07-14 BR BR112019000788A patent/BR112019000788A2/pt unknown
- 2017-07-14 ES ES17746011T patent/ES2903412T3/es active Active
-
2019
- 2019-01-08 US US16/242,760 patent/US10696741B2/en active Active
- 2019-01-10 SA SA519400856A patent/SA519400856B1/ar unknown
- 2019-10-23 US US16/661,757 patent/US11261246B2/en active Active
- 2019-10-23 US US16/661,783 patent/US11447544B2/en active Active
-
2022
- 2022-02-04 CY CY20221100099T patent/CY1125041T1/el unknown
- 2022-08-11 US US17/819,161 patent/US20230088269A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| UY40829A (es) | Anticuerpos anti-phf-tau y sus usos | |
| CO2019013935A2 (es) | Anticuerpos que se unen específicamente a pd-1 y métodos de uso | |
| MX2019000539A (es) | Anticuerpos anti-il-22r. | |
| CO2018011364A2 (es) | Anticuerpos anti-il-33, composiciones, métodos y usos de los mismos | |
| CO2018001149A2 (es) | Anticuerpos monoclonales contra bcma | |
| CO2019001246A2 (es) | Anticuerpos anti-pd-1, un método de producción y un método para su uso | |
| MX381046B (es) | Anticuerpos anti-csf1r e inhibidores de pd-1/pd-l1, y usos de los mismos para el tratamiento de cáncer remisión a las solicitudes relacionadas. | |
| CO2018010458A2 (es) | Composiciones y anticuerpos anti-tim-3 | |
| MX2022011002A (es) | Anticuerpos de grupo de diferenciacion 3 (cd3) humanizados o quimericos. | |
| ECSP18041833A (es) | Anticuerpos que se unen específicamente a pd-1 y sus usos | |
| MX2022014695A (es) | Anticuerpos anti-gitr y sus usos. | |
| CU24498B1 (es) | Anticuerpos de factor xi | |
| BR112017006468A2 (pt) | anticorpo biespecífico, composição farmacêutica, kit, uso de uma combinação de um anticorpo biespecífico e método de tratamento de câncer | |
| CO2017005941A2 (es) | Composiciones y métodos para anticuerpos dirigidos a bmp6 | |
| MX388181B (es) | Anticuerpos anti-pd-1. | |
| MX2022007676A (es) | Anticuerpos caninizados biespecificos para tratar dermatitis atopica. | |
| MX2022015250A (es) | Un anticuerpo anti-il-23a para usarse en el tratamiento de la enfermedad de crohn. | |
| MX2017010037A (es) | Metodos de tratamiento de enfermedades inflamatorias. | |
| CO2018001840A2 (es) | Composiciones biofarmacéuticas que comprenden anticuerpos anti-il-5 | |
| CL2016001979A1 (es) | Métodos de tratamiento de enfermedad de alzheimer. | |
| CL2016001753A1 (es) | Anticuerpo monoclonal humanizado que se une específicamente a netrina-1, composiciones farmacéuticas y usos del anticuerpo para el tratamiento del cáncer | |
| MX2018013222A (es) | Anticuerpos de interferon beta y usos de los mismos. | |
| MX2020009130A (es) | Anticuerpos terapéuticos anti-spla2-gib y los usos de los mismos. | |
| CL2025000292A1 (es) | Anticuerpos tmem219 y usos terapéuticos de los mismos | |
| MX392703B (es) | Uso de anticuerpos anti-il-23a para tratar psoriasis pustulosa generalizada. |